AstraZeneca (NYSE: AZN) and Nektar Therapeutics (Nasdaq: NKTR) entered into an exclusive worldwide license agreement for two drug development programmes ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE